Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs KraneShares CSI China Internet ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.28 (market cap $8.04B), while KraneShares CSI China Internet ETF trades at $27.3. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| BIO | KWEB | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $339.75 | $42.94 |
52-Week Low | $241.71 | $23.63 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
KWEB trades at $26.23, down 0.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to Chinese internet and AI companies, benefiting from government support and AI-driven growth, though key financial ratios are unavailable. Recent news highlights China's push for tech self-reliance and strong export performance.
Outlook is mixed: AI expansion and attractive valuations offer upside, but geopolitical tensions and regulatory risks pose challenges. The stock's performance hinges on China's economic policies and global tech competition, requiring careful risk assessment for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
